| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash | 69,555 | |||
| Accounts receivable, related party-Related Party | 204,873 | |||
| Prepaid expenses | 200 | |||
| Total current assets | 274,628 | |||
| Total assets | 274,628 | |||
| Accounts payable | 1,714 | |||
| Accrued expenses | 1,838,230 | |||
| Notes payable-Related Party | 191,339 | |||
| Unearned income | 1,338,611 | |||
| Derivative liability | 2,079,618 | |||
| Convertible notes payable, net of unamortized debt discount | 1,006,521 | |||
| Other current liabilities | 99,776 | |||
| Total current liabilities | 6,555,811 | |||
| Total liabilities | 6,555,811 | |||
| Common stock (.0001 par value) 5,800,000,000 authorized and 39,374,704 and 5,258,235 shares issued and outstanding, respectively | 3,939 | |||
| Preferred stock, value-Series APreferred Stock | 1,011 | |||
| Preferred stock, value-Series MPreferred Stock | 3 | |||
| Preferred stock, value-Series NCPreferred Stock | 2 | |||
| Additional paid in capital | 15,628,062 | |||
| Other comprehensive income | -222,580 | |||
| Retained earnings (deficit) | -21,691,620 | |||
| Total stockholders equity (deficit) | -6,281,183 | |||
| Total liabilities & stockholders equity (deficit) | 274,628 | |||
Regen BioPharma Inc (RGBP)
Regen BioPharma Inc (RGBP)